Anlon Healthcare Q1FY26 Results Show Mixed Performance
Anlon Healthcare Limited released Q1FY26 results, showing a 12% YoY revenue decline to ₹3,329.72 lacs. Net profit decreased by 5.8% to ₹354.69 lacs. Despite revenue challenges, the company demonstrated effective cost management with total expenses down 12.6%. Notably, earnings per share significantly improved to ₹2.22 from ₹0.41 in Q1FY25, a 441.5% increase. The balance sheet strengthened with total assets rising to ₹19,775.76 lacs and total equity increasing to ₹8,396.86 lacs.
*this image is generated using AI for illustrative purposes only.
Anlon Healthcare Limited released its unaudited standalone financial results for the first quarter of fiscal year 2026, covering the period ended June 30, 2025. The pharmaceutical company, which specializes in manufacturing Active Pharmaceutical Ingredients (APIs) and drug intermediates, demonstrated mixed performance with maintained profitability despite revenue challenges.
Financial Performance Overview
Anlon Healthcare reported a net profit of ₹354.69 lacs for Q1FY26, down from ₹376.35 lacs in Q1FY25. The company's revenue declined by 12% year-over-year to ₹3,329.72 lacs. Despite the revenue decrease, the company showed strong operational efficiency improvements.
The company's financial metrics for Q1FY26 showed both strengths and areas of concern when compared to the corresponding quarter of the previous year:
| Metric | Q1FY26 | Q1FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations | 3329.72 | 3783.25 | -12.0% |
| Total Income | 3330.89 | 3789.34 | -12.1% |
| Total Expenses | 2830.48 | 3236.83 | -12.6% |
| Profit Before Tax | 500.41 | 552.51 | -9.4% |
| Net Profit After Tax | 354.69 | 376.35 | -5.8% |
| Earnings Per Share (Basic) | 2.22 | 0.41 | +441.5% |
Revenue and Operational Analysis
Revenue from operations declined by 12.0% year-on-year to ₹3,329.72 lacs in Q1FY26 from ₹3,783.25 lacs in Q1FY25. Other income remained minimal at ₹1.17 lacs compared to ₹6.09 lacs in the previous year quarter. The company's total income decreased to ₹3,330.89 lacs from ₹3,789.34 lacs, reflecting the challenging market conditions in the pharmaceutical sector.
Cost Management and Profitability
Despite the revenue decline, Anlon Healthcare demonstrated effective cost management strategies. Total expenses decreased by 12.6% to ₹2,830.48 lacs from ₹3,236.83 lacs in Q1FY25. Key expense components showed the following changes:
- Cost of materials consumed increased to ₹2,959.48 lacs from ₹1,949.10 lacs
- Employee benefits expense rose to ₹122.49 lacs from ₹116.41 lacs
- Finance costs decreased to ₹81.71 lacs from ₹98.39 lacs
- Other expenses declined to ₹161.31 lacs from ₹201.92 lacs
Balance Sheet Strength
The company's balance sheet as of June 30, 2025, showed total assets of ₹19,775.76 lacs compared to ₹18,129.99 lacs as of March 31, 2025. Total equity increased to ₹8,396.86 lacs from ₹8,042.17 lacs, indicating strengthened shareholder value. Current assets grew significantly to ₹17,534.74 lacs from ₹15,848.09 lacs, primarily driven by increased trade receivables and inventory levels.
Cash Flow and Liquidity Position
Anlon Healthcare generated positive cash flow from operating activities of ₹117.88 lacs during the quarter. The company maintained adequate liquidity with cash and cash equivalents of ₹185.67 lacs as of June 30, 2025, compared to ₹144.96 lacs at the beginning of the period. Net cash used in financing activities was ₹74.37 lacs, while investing activities consumed ₹2.80 lacs.
Earnings Per Share Performance
Notably, the company's earnings per share showed remarkable improvement, rising to ₹2.22 in Q1FY26 from ₹0.41 in Q1FY25. This significant increase reflects the company's focus on operational efficiency and cost optimization despite the challenging revenue environment. Both basic and diluted earnings per share remained at ₹2.22 for the quarter.
Historical Stock Returns for Anlon Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.29% | -4.41% | -2.85% | +57.31% | +57.31% | +57.31% |
16
